Myopericarditis, has emerged as an important adverse event following COVID-19 mRNA vaccination, particularly in adolescents [[1]]. Patients typically exhibit chest pain and an elevated serum troponin level in the days following the COVID-19 mRNA vaccine. They usually are hemodynamically stable, and symptoms and cardiac biomarkers normalize within a few days [[2]]. cardiac magnetic resonance studies, when performed early, frequently demonstrate abnormalities such as edema and late gadolinium enhancement (LGE), meeting Lake Louise Criteria for diagnosing myocarditis noninvasively [[2],[3]]. In classical myocarditis LGE can be predictive of a poor outcome [[5]]. Little is known about the prognostic value or expected evolution of these CMR abnormalities associated with post-COVID-19 mRNA vaccine myopericarditis. In this case series we report the evolution of CMR imaging compared with initial, acute phase, CMR in our cohort of patients with myopericarditis post COVID-19 mRNA vaccine.
SOURCES:
https://www.jpeds.com/article/S0022-3476(22)00282-7/fulltext#relatedArticles
https://t.me/s/Doctorsforcovidethics

Mirrored - Boot Camp

Shared from and subscribe to:
The Prisoner
https://www.brighteon.com/channels/theprisoner